紫杉醇、顺铂在进展期食管癌化疗中的临床效果及对患者血清肿瘤标记物的影响

打开文本图片集

中图分类号：R734.2文献标识码：A

DOI：10.3969/j.issn.1006-1959.2025.16.015 文章编号：1006-1959（2025）16-0078-04

Clinical Effect of Paclitaxel and Cisplatin in the Chemotherapyof Advanced Esophageal Cancer and itsEffects on Serum Tumor Markers

WANG Zhichun

（Tumor HematologyDepartmentofShangyou CountyPeople'sHospital，Shangyou3412Oo，Jiangxi，China）

Abstract：ObjetieTtualtfcliaeldsplatiinemoteaofdacdopealcrCdt serumtuormarkersMethodsSitypatientswithdvancedECadmitedtoShangyouCountyPeople'sHospialfromJanuary221toJune202 weredividedintoFoupOpatints）douppatints）bydoumberablemetodFgoupastreateditfuoousp chemotherapyregimenandTPgroupastreatedwithpaclitaxel+cisplatinchemotherapyregimen.Theclinicalefects，serumtuorarkes [carcinoembryoictign（EA）bohratetigen9-9CA9-9）toxicndidftsualtoflifeeineeversiof AndersonSymptomsessmentScale（A-C）QualityofLifeIstruentsforroiciseasesithEohagealCaer（I）ere compared between the two groups.Results The tumor control rate of TP group （96.67 % ）washigher than that ofFP group （83.33 % ） P< 0.05）.The levelsofCEAandCA19-9intetwogroupsaftertreatmenwerelowertanthoseeforetreamentandthelevelsofCEAandCA19-9iteT group were lower than those in the FP group（ P< 0.05）.There was no significant diference in the incidence of toxic and side effects between the two groups（ P> 0.05）.Aftetreatment，theMDASI-CsoreofthetwogroupswaslowerthanthatbeforetreatmentndtheQLICD-ESsoreashigher thanthatbeforetreantsellseA-CoroftoualoerantatofthopdCDSeae than that of the FP group（ P<0.05） .Conclusion Paclitaxel and cisplatin can play agood therapeutic role in the chemotherapy of advanced EC，and itslinicalecelutetofkeitsideyds the quality of life.

Key Words：Advanced esophageal cancer;Paclitaxel; Cisplatin; Serum tumor markers;Quality of life

食管癌（esophagealcancer，EC）为我国高发消化道恶性肿瘤疾病，其早期病变多不明显，多数患者确诊时已处于疾病进展期阶段，需行化疗等治疗手段，以控制肿瘤进展，延长其生存期限[2]。（剩余5556字）